CL2008001446A1 - Uso de un probiotico o mezcla de los mismos en la elaboracion de una composicion nutricional o farmaceutica para actuar en el colon en un ambiente pre- o post-quirurgico. - Google Patents

Uso de un probiotico o mezcla de los mismos en la elaboracion de una composicion nutricional o farmaceutica para actuar en el colon en un ambiente pre- o post-quirurgico.

Info

Publication number
CL2008001446A1
CL2008001446A1 CL2008001446A CL2008001446A CL2008001446A1 CL 2008001446 A1 CL2008001446 A1 CL 2008001446A1 CL 2008001446 A CL2008001446 A CL 2008001446A CL 2008001446 A CL2008001446 A CL 2008001446A CL 2008001446 A1 CL2008001446 A1 CL 2008001446A1
Authority
CL
Chile
Prior art keywords
probiotic
elaboration
colon
nutritional
act
Prior art date
Application number
CL2008001446A
Other languages
English (en)
Spanish (es)
Inventor
Eduardo Schiffrin
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CL2008001446A1 publication Critical patent/CL2008001446A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2008001446A 2007-05-18 2008-05-16 Uso de un probiotico o mezcla de los mismos en la elaboracion de una composicion nutricional o farmaceutica para actuar en el colon en un ambiente pre- o post-quirurgico. CL2008001446A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07108492.5A EP1992351B1 (en) 2007-05-18 2007-05-18 Lactobacillus johnsonii for prevention of postsurgical infection

Publications (1)

Publication Number Publication Date
CL2008001446A1 true CL2008001446A1 (es) 2009-10-02

Family

ID=38476047

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001446A CL2008001446A1 (es) 2007-05-18 2008-05-16 Uso de un probiotico o mezcla de los mismos en la elaboracion de una composicion nutricional o farmaceutica para actuar en el colon en un ambiente pre- o post-quirurgico.

Country Status (15)

Country Link
US (2) US8529887B2 (cg-RX-API-DMAC10.html)
EP (2) EP1992351B1 (cg-RX-API-DMAC10.html)
JP (2) JP5497634B2 (cg-RX-API-DMAC10.html)
CN (2) CN103623010A (cg-RX-API-DMAC10.html)
AU (1) AU2008253040B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0811180A2 (cg-RX-API-DMAC10.html)
CA (1) CA2686976C (cg-RX-API-DMAC10.html)
CL (1) CL2008001446A1 (cg-RX-API-DMAC10.html)
DK (1) DK1992351T3 (cg-RX-API-DMAC10.html)
ES (1) ES2578261T3 (cg-RX-API-DMAC10.html)
MX (1) MX2009012255A (cg-RX-API-DMAC10.html)
RU (1) RU2470652C2 (cg-RX-API-DMAC10.html)
TW (1) TW200902040A (cg-RX-API-DMAC10.html)
WO (1) WO2008141989A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200909002B (cg-RX-API-DMAC10.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992351B1 (en) * 2007-05-18 2016-05-11 Nestec S.A. Lactobacillus johnsonii for prevention of postsurgical infection
US8825503B2 (en) * 2008-05-15 2014-09-02 Youdocs, Llc Methods and systems for improving human health using targeted probiotics
US9474773B2 (en) 2009-02-18 2016-10-25 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
WO2010096564A2 (en) * 2009-02-19 2010-08-26 Probiohealth Llc Dietary supplements containing polyunsaturated omega-3 fatty acids and probiotic bacteria with potential gastrointestinal and dermatological benefits
US9173760B2 (en) 2009-04-03 2015-11-03 Metamodix, Inc. Delivery devices and methods for gastrointestinal implants
US9278019B2 (en) 2009-04-03 2016-03-08 Metamodix, Inc Anchors and methods for intestinal bypass sleeves
ES2503553T3 (es) 2009-04-03 2014-10-07 Metamodix, Inc. Prótesis gastrointestinales modulares
US8784798B2 (en) * 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
EP2251022A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Non-replicating micro-organisms and their immune boosting effect
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
DK2459203T3 (en) 2009-07-30 2019-02-18 Dupont Nutrition Biosci Aps Lactic Acid Bacteria and Bifidobacteria for the Treatment of Endotoxemia
PH12013501773A1 (en) * 2011-03-31 2013-10-14 Nestec Sa Nutritional compositions for increasing arginine levels and methods of using same
DK2693885T3 (en) 2011-04-08 2018-05-22 Chr Hansen As Synergistic antimicrobial effect
CN103648511B (zh) * 2011-06-08 2018-12-07 诺沃奇梅兹有限公司 喷雾干燥的乳杆菌属菌株/细胞及其对抗幽门螺杆菌的用途
CN102835657B (zh) * 2011-06-20 2014-08-20 丰华生物科技股份有限公司 用以抑制发炎反应及抗阴道炎的含乳酸菌食品组合物及医药组合物
IN2014DN07752A (cg-RX-API-DMAC10.html) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
EP2830599B1 (en) 2012-03-29 2018-08-15 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
AR090631A1 (es) * 2012-04-09 2014-11-26 Chr Hansen As Bioproteccion que usa cepas lactobacillus rhamnosus
UA115331C2 (uk) 2012-04-09 2017-10-25 Кр. Хансен А/С Біозахист з використанням штамів lactobacillus paracasei
WO2014113483A1 (en) * 2013-01-15 2014-07-24 Metamodix, Inc. System and method for affecting intestinal microbial flora
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
RU2565444C2 (ru) * 2013-11-28 2015-10-20 Федеральное государственное бюджетное учреждение науки Институт клеточного и внутриклеточного симбиоза Уральского отделения Российской академии наук Способ профилактики инфекционно-воспалительных осложнений у женщин с субмукозной миомой матки после гистерорезектоскопии
KR101445243B1 (ko) * 2014-03-28 2014-09-29 서울대학교산학협력단 장내 세균의 군집과 기능의 변화를 이용한 대사성 및 염증성 질환의 조기진단
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
US9622897B1 (en) 2016-03-03 2017-04-18 Metamodix, Inc. Pyloric anchors and methods for intestinal bypass sleeves
US10751209B2 (en) 2016-05-19 2020-08-25 Metamodix, Inc. Pyloric anchor retrieval tools and methods
RU2628063C1 (ru) * 2016-09-22 2017-08-14 федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) Способ прогнозирования транслокации E.coli из кишечника при некультивируемом типе инфекционного процесса в эксперименте на кроликах
RU2642327C1 (ru) * 2016-10-06 2018-01-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) Способ прогноза развития патогенетического процесса по некультивируемому или культивируемому типу в эксперименте
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
TWI718402B (zh) * 2018-08-16 2021-02-11 葡萄王生技股份有限公司 副乾酪乳酸桿菌gks6之活性物質、含其之組合物及其促進長壽之用途
TWI784194B (zh) * 2019-09-04 2022-11-21 台達電子工業股份有限公司 抑制具萬古黴素抗藥性腸球菌之益生菌組合與其用途
CN112438995A (zh) 2019-09-04 2021-03-05 台达电子工业股份有限公司 抑制具万古霉素抗药性肠球菌的益生菌及其组合与其用途
US20220193156A1 (en) * 2020-12-23 2022-06-23 Thi Tuyet Mai Ta Preoperative compositions and methods of preparation thereof
US12377123B2 (en) * 2020-12-23 2025-08-05 Preoperative Nutrition Preoperative compositions and methods of preparation thereof
CN113559131A (zh) * 2021-07-23 2021-10-29 科为博(江苏)生物科技研究院有限公司 一种用于改善肠胃的益生菌粉

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2124060T5 (es) * 1992-07-06 2002-12-16 Nestle Sa Bacteria lactica.
ATE161181T1 (de) * 1992-07-06 1998-01-15 Nestle Sa Lactobacillus acidophilus enthaltende antigastritis-mittel
DE29724815U1 (de) * 1997-01-09 2004-07-22 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
IT1289984B1 (it) * 1997-02-27 1998-10-19 Proge Farm Srl Ceppi di lattobacilli utili nel trattamento di disfunzioni del sistema gastrointestinale
DK1003532T4 (da) 1997-07-05 2009-03-02 Nestle Sa Lactobacilli til fremme af tarmcellers mineralabsorption
RO112995B1 (ro) * 1997-08-05 1998-03-30 Rodica Teodorescu Produs medicamentos pentru terapia colonului
ATE348626T1 (de) * 2000-03-24 2007-01-15 Nestle Sa Milchsäurebakterium zur prävention der bauchfellentzündung
US7794744B2 (en) * 2000-04-18 2010-09-14 Nestec S.A. Nutritional modules
GB0027761D0 (en) 2000-11-14 2000-12-27 Nestle Sa Nutritional composition for an immune condition
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
SI1565547T2 (sl) * 2002-06-28 2013-02-28 Biosearch S.A. Probiotiäśni sevi, postopek za izbiranje le-teh, njihovi sestavki in njihova uporaba
CN1863463B (zh) * 2003-06-23 2011-05-04 雀巢技术公司 用于促进肠道屏障成熟的营养组合物
KR20060109452A (ko) * 2003-10-02 2006-10-20 더 바이오 밸런스 코포레이션 건조 바이오치료 조성물, 용도, 그 투여 장치 및 투여 방법
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
WO2006046871A2 (en) * 2004-10-29 2006-05-04 N.V. Nutricia Peri-operative composition comprising lactobacillus rhamnosus
US7595079B2 (en) * 2005-07-08 2009-09-29 Bomac Vets Plus, Inc. Nutritional conjunctive support therapy for recovery in animals following stress or illness
RU2293568C1 (ru) * 2006-01-10 2007-02-20 Федеральное государственное учреждение Российский центр функциональной хирургической гастроэнтерологии Федерального агентства по здравоохранению и социальному развитию (ФГУ "РЦФХГ Росздрава") Способ периоперационной коррекции дисбиоза толстой кишки у больных колоректальным раком
EP1992351B1 (en) * 2007-05-18 2016-05-11 Nestec S.A. Lactobacillus johnsonii for prevention of postsurgical infection

Also Published As

Publication number Publication date
CN103623010A (zh) 2014-03-12
JP2013216658A (ja) 2013-10-24
ES2578261T3 (es) 2016-07-22
ZA200909002B (en) 2011-02-23
TW200902040A (en) 2009-01-16
EP2146729A1 (en) 2010-01-27
MX2009012255A (es) 2009-11-25
US20100135971A1 (en) 2010-06-03
US8529887B2 (en) 2013-09-10
EP1992351A1 (en) 2008-11-19
CA2686976C (en) 2015-02-17
BRPI0811180A2 (pt) 2014-10-21
US9616094B2 (en) 2017-04-11
CN101678054A (zh) 2010-03-24
RU2470652C2 (ru) 2012-12-27
US20130344044A1 (en) 2013-12-26
JP2010527343A (ja) 2010-08-12
AU2008253040B2 (en) 2014-06-12
WO2008141989A1 (en) 2008-11-27
AU2008253040A1 (en) 2008-11-27
EP1992351B1 (en) 2016-05-11
CA2686976A1 (en) 2008-11-27
JP5497634B2 (ja) 2014-05-21
RU2009147036A (ru) 2011-06-27
JP6285108B2 (ja) 2018-02-28
DK1992351T3 (en) 2016-06-06

Similar Documents

Publication Publication Date Title
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2011002739A1 (es) Compuestos derivados de 3-(1h-pirrolo[2,3-b]piridina-3-carbonil)-bencenosulfonamida; composicion farmaceutica que los comprende; kit; y su uso como inhibidores de raf para el tratamiento de una enfermedad o condicion seleccionada de melanoma, glioma, glioblastoma multiforme, cancer colorrectal, cancer de pulmon, entre otras.
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
EA201000784A1 (ru) Антагонисты пути hedgehog и их терапевтические применения
CR11232A (es) Compuestos de tiazolopirina modulares de sirtuina
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
AR069474A1 (es) Material anticorrosivo
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
UY30304A1 (es) Moduladores de mglur5 i
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
CL2008001540A1 (es) Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
CL2008000510A1 (es) Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero.
CL2011000562A1 (es) Compuesto derivado de tetraciclina; util en el tratamiento de artritis reumatoide.
UY30308A1 (es) Moduladores de mglur5 v
CL2012002173A1 (es) Combinacion de al menos un estimulador o activador de la sgc con un inhibidor de la pde5; formulacion farmaceutica; y uso para el tratamiento de la fibrosis quistica.
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
UY30307A1 (es) Moduladores de mglur5 vi
AR053803A1 (es) Uso de acido pinolenico
CL2014001399A1 (es) Compuestos de reversion anticoagulante; composicion farmaceutica y el uso de los mismos para revertir el efecto anticoagulante de un inhibidor de la coagulacion.
CL2013003125A1 (es) Compuestos derivados de isoxazolinas inhibidores mps; composicion farmaceutica que los comprende; kit farmaceutico; y uso en el tratamiento de una enfermedad tales como osteoartritis, artritis reumatoide, artritis juvenil, artritis psoriasica, lupus eritematoso sistemico, entre otras.
UY30309A1 (es) Moduladores de mglur5 ii
CL2013001945A1 (es) Compuestos derivados de pirazol de fórmulas (ia) o (ib), antagonistas de crth2; composiciones farmaceuticas que los contienen; combinaciones farmaceuticas; su uso en la prevencion y/o el tratamiento de trastornos inflamatorios, infecciosos e inmunorreguladores.